• Acura Pharmaceuticals filed a Form NT 10-Q, delaying its quarterly report for the period ended June 30, 2026.
• The delay was tied to liquidity pressure and uncertainty about meeting day-to-day operating obligations.
• Funding depends on loans from Abuse Deterrent Pharma, LLC, with no assurance of continued or sufficient support.
• The company has not filed annual reports for 2022-2025 or quarterly reports for 2022-2025 and the quarter ended March 31, 2026.
• Audit and review work has been halted or not engaged for 2022-2026 results, raising uncertainty about when filings will resume.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-101083), on August 26, 2026, and is solely responsible for the information contained therein.